Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.47 |
| ▸ | TYMS | P04818 | 1/20 | 0.43 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.42 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | TK1 | P04183 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | THPO | P40225 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.40 |
| ▸ | HBB | P68871 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12732344 | 1.00 | SLC29A1 (0.47) | SLC29A1TYMSADRB1DNMT1LMNA | |
| SCHEMBL10183365 | 1.00 | SLC29A1 (0.47) | SLC29A1TYMSADRB1DNMT1LMNA | |
| SCHEMBL13030145 | 1.00 | SLC29A1 (0.47) | SLC29A1TYMSADRB1DNMT1LMNA | |
| SCHEMBL21067741 | 0.86 | TYMS (0.58) | TYMS | |
| SCHEMBL21067742 | 0.86 | TYMS (0.58) | TYMS | |
| SCHEMBL13030152 | 0.81 | SLC29A1 (0.47) | SLC29A1TYMSADRB1DNMT1CYP1A2 | |
| SCHEMBL14534827 | 0.81 | LMNA (0.49) | SLC29A1LMNASMN1; SMN2CYP1A2NFKB1 | |
| SCHEMBL14084325 | 0.81 | LMNA (0.49) | SLC29A1LMNASMN1; SMN2CYP1A2NFKB1 | |
| SCHEMBL1062447 | 0.81 | LMNA (0.49) | SLC29A1LMNASMN1; SMN2CYP1A2NFKB1 | |
| SCHEMBL29446054 | 0.81 | LMNA (0.49) | SLC29A1LMNASMN1; SMN2CYP1A2NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1641942-A2 | COMBINATORIAL NUCLEOBASE OLIGOMERS COMPRISING UNIVERSAL BASE ANALOGUES AND METHODS FOR MAKING AND USING SAME | Applera Corporation (US) | 2006-04-05 | — | — | EP | claimed |
| US-20050053979-A1 | Combinatorial nucleobase oligomers comprising universal base analogues and methods for making and using same | APPLIED BIOSYSTEMS, LLC | 2005-03-10 | — | — | US | claimed |
| WO-2004111072-A2 | COMBINATORIAL NUCLEOBASE OLIGOMERS COMPRISING UNIVERSAL BASE ANALOGUES AND METHODS FOR MAKING AND USING SAME | APPLERA CORPORATION (US) | 2004-12-23 | — | — | WO | claimed |
| EP-1994182-B1 | DEGENERATE NUCLEOBASE ANALOGS | SIEMENS HEALTHCARE DIAGNOSTICS INC (US) | 2019-05-29 | — | — | EP | disclosed |
| US-9677123-B2 | Degenerate nucleobase analogs | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2017-06-13 | — | — | US | disclosed |
| EP-1700922-B1 | 3-Substituted 5-Nitroindole derivatives and labeled oligonucleotide probes containing them | ROCHE DIAGNOSTICS GMBH (DE) | 2016-08-24 | — | — | EP | disclosed |
| US-7759469-B2 | substituted indole nucleosides as both terminal as well as internal building blocks of labeled oligonucleotide probes for the detection, analysis and quantitation of nucleic acids; nucleoside with a 3-substituted methanesulfonylamino indole as nucleobase | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2010-07-20 | — | — | US | disclosed |
| US-20100055798-A1 | Degenerate Nucleobase Analogs | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2010-03-04 | — | — | US | disclosed |
| EP-1994182-A2 | DEGENERATE NUCLEOBASE ANALOGS | Siemens Healthcare Diagnostics Inc. (US) | 2008-11-26 | — | — | EP | disclosed |
| WO-2007106690-A2 | DEGENERATE NUCLEOBASE ANALOGS | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2007-09-20 | — | — | WO | disclosed |
| US-20060216736-A1 | Labeling reagent | ROCHE DIAGNOSTICS OPERTIONS, INC. (US) | 2006-09-28 | — | — | US | disclosed |
| EP-1641942-A2 | COMBINATORIAL NUCLEOBASE OLIGOMERS COMPRISING UNIVERSAL BASE ANALOGUES AND METHODS FOR MAKING AND USING SAME | Applera Corporation (US) | 2006-04-05 | — | — | EP | disclosed |
| US-20050053979-A1 | Combinatorial nucleobase oligomers comprising universal base analogues and methods for making and using same | APPLIED BIOSYSTEMS, LLC | 2005-03-10 | — | — | US | disclosed |
| WO-2004111072-A2 | COMBINATORIAL NUCLEOBASE OLIGOMERS COMPRISING UNIVERSAL BASE ANALOGUES AND METHODS FOR MAKING AND USING SAME | APPLERA CORPORATION (US) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050053979-A1 | Combinatorial nucleobase oligomers comprising universal base analogues and methods for making and using same | DTYMK, UNG, TPR | SLC29A1 430/4885TYMS 7/4885ADRB1 4604/4885 |
| US-20060216736-A1 | Labeling reagent | DUT, NUDT1, NT5C2 | SLC29A1 42/4885TYMS 52/4885ADRB1 2189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.